Anaemia of prematurity. Epidemiology, management and costs.
Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is inadequate), and the risk of transfusion-related infection is decreased. Nevertheless, rHuEpo is relatively expensive (a 6-week course costs approximately the same as 2 blood transfusions), so its use requires careful consideration; it is logical to target rHuEpo therapy to those babies who are most likely to be transfused. Using this strategy, 1 study involving stable growing preterm infants has shown that direct costs of blood transfusion and rHuEpo were similar, and the use of rHuEpo was recommended. In addition, use of high-dosage rHuEpo early in the course of management on the neonatal intensive care unit has been shown to reduce direct treatment costs in ill preterm infants. Further studies will continue to identify infants who are likely to benefit from rHuEpo therapy and to define its cost effectiveness in more detail.
Meyer
M P
MP
Special Care Baby Unit, Middlemore Hospital, Auckland, New Zealand. mmeyer@ww.co.nz
D000751:Anemia, Neonatal / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D004921:Erythropoietin / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D011994:Recombinant Proteins